Arrowstreet Capital, Limited Partnership Avadel Pharmaceuticals PLC Transaction History

Arrowstreet Capital, Limited Partnership

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$7.25 - $11.75 $109,946 - $178,188	-15,165 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$4.06 - $10.64 $353,244 - $925,743	-87,006 Reduced 85.16%	15,165 $120,000
Q4 2019 Feb 13, 2020	BUY	$3.34 - $7.7 $341,251 - $786,716	102,171 New	102,171 $771,000
Q3 2018 Nov 14, 2018	SELL	$4.08 - $7.14 $47,833 - $83,709	-11,724 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$5.89 - $7.78 $69,054 - $91,212	11,724 New	11,724 $72,000
Q4 2017 Feb 09, 2018	SELL	$8.03 - $11.25 $160,600 - $225,000	-20,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$8.35 - $10.5 $167,000 - $210,000	20,000	20,000 $210,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $626M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.